Welcome to our dedicated page for Cingulate SEC filings (Ticker: CINGW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cingulate Inc. (CINGW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Cingulate files a range of documents with the U.S. Securities and Exchange Commission that together outline its financial condition, capital structure, governance, and progress in developing its Precision Timed Release™ (PTR™) platform and lead ADHD candidate, CTx-1301.
Among the most relevant filings for CINGW are Form 10-Q quarterly reports and Form 10-K annual reports, which detail operating expenses such as research and development and general and administrative costs, net losses, cash and working capital levels, and accumulated deficit. These reports also discuss key milestones, including the submission and FDA acceptance of the New Drug Application (NDA) for CTx-1301 under the 505(b)(2) pathway and the assignment of a Prescription Drug User Fee Act (PDUFA) target action date.
Cingulate’s Form 8-K current reports are especially important for tracking material events. Recent 8-Ks describe unregistered sales of equity securities, executive and board changes, the submission of the CTx-1301 NDA, and the announcement of quarterly financial results via press release. Other filings, such as Form NT 10-Q, explain delays in periodic reports and reference management transitions, while the DEF 14A proxy statement for a special meeting outlines stockholder votes on equity issuance under a purchase agreement with Lincoln Park Capital.
For investors focused on the CINGW warrants and capital structure, filings like the Form S-1/A registration statement and related 8-Ks provide detail on committed equity facilities, warrant listings, and share issuances to lenders or service providers. On Stock Titan, these filings are updated in near real time from EDGAR, and AI-powered summaries help explain complex sections, such as equity financing terms, executive compensation arrangements, and risk disclosures, so users can more quickly interpret how each document may affect Cingulate’s development and financing plans.
Cingulate Inc. reported interim financials showing significant operating losses and active equity financings. The company recorded operating loss of $8,356,009 for the six-month period and a loss before income taxes of $(4,788,735) for the three-month period, with an accumulated deficit of approximately $117.1 million. Cash-raising activity included at-the-market sales and Lincoln Park purchase agreements providing net proceeds (examples: $2,599,099 under the ATM during six months ended June 30, 2025 and $3,513,236 under the Original LP Purchase Agreement during the same period). The company disclosed a $5.48 million unsecured promissory note with a 9% coupon and material default penalty mechanics. Management stated there is substantial doubt about the company’s ability to continue as a going concern within one year and noted efforts to seek additional equity, debt, or strategic transactions. The financial statements are unaudited interim results prepared on a going concern basis.
Cingulate Inc. submitted a current report describing that it released financial results for the quarter ended June 30, 2025. On August 19, 2025, the company issued a press release with these quarterly results and recent business highlights, and furnished that press release as Exhibit 99.1. The company notes that this press release is being furnished rather than filed, which limits how it is treated under certain securities law liability provisions and how it is incorporated into other regulatory documents.
Cingulate Inc. is calling a virtual special meeting on September 25, 2025 to ask stockholders to approve issuing more than 20% of its outstanding common stock under a purchase agreement with Lincoln Park Capital Fund, LLC. This approval is needed to comply with Nasdaq Listing Rule 5635(d) so the company can sell additional shares beyond a 19.99% cap in a private financing.
Under the agreement, Lincoln Park has committed to buy up to $25.0 million of Cingulate common stock over 36 months, and has already received 120,424 commitment shares. As of August 1, 2025, Cingulate had 5,264,642 shares outstanding. The company plans to use any proceeds from sales to Lincoln Park mainly for regulatory approval and development, manufacturing and commercialization activities for CTx-1301, as well as working capital and general corporate purposes. Stockholders are also being asked to approve a potential adjournment of the meeting if more time is needed to gather votes.
Cingulate Inc. reported that on August 7, 2025, the employment of Laurie A. Myers, its Executive Vice President and Chief Operating Officer, terminated. This means a key operating leadership role at the company is now vacant, and the company may need to adjust responsibilities or appoint a successor to oversee day-to-day operations and execution.
FAQ
What is the current stock price of Cingulate (CINGW)?
